Heart failure & cardiomyopathiesCohort study

Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform

Heart RhythmPublished

  • single-center retrospective study
  • time-slicing convolutional neural network
  • training/validation and test data sets stratified by amyloidosis status, sex, and age groups

Authors' conclusion

This work expands Willem AI capabilities, enabling automated ATTR-CM detection from routine 12-lead ECGs in a real-world referral population. The Willem AI model may support informed clinical management and scalable triage to trigger confirmatory testing and accelerate diagnosis.

Study context

Population
Adults evaluated for ATTR-CMindividuals, 20,754 electrocardiograms (ECGs) after quality control · patients with ATTR-CM 585 · controls 2,316
Participants
2,901 adults
Exposure
Willem artificial intelligence (AI) ATTR-CM detection from 12-lead ECGs
  • patients with ATTR-CMn = 585
  • controlsn = 2,316

Main finding

As reported in the abstract

Willem AI diagnostic performance · test cohort

AUC

0.88 (95% confidence interval, 0.85-0.91)

sensitivity

80.7%

specificity

78.5%

Observational data: associations, not effects.

Further findings

Performance by ATTR type

ATTRv AUC
0.91
ATTRwt AUC
0.88

Sensitivity in early presentations

asymptomatic sensitivity
68.4%
New York Heart Association class I sensitivity
73.9%

Performance in red-flag scenarios

carpal tunnel syndrome AUC
0.92
lumbar spinal stenosis AUC
0.92
polyneuropathy AUC
0.91

Original publication

Improving transthyretin cardiac amyloidosis detection from electrocardiograms through the Willem artificial intelligence platform. Heart Rhythm. Published 1 April 2026. doi:10.1016/j.hrthm.2026.03.1949

Summarised from the published abstract; every number is checked against it